Cargando…

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of thes...

Descripción completa

Detalles Bibliográficos
Autores principales: De Plano, Laura M., Calabrese, Giovanna, Conoci, Sabrina, Guglielmino, Salvatore P. P., Oddo, Salvatore, Caccamo, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368966/
https://www.ncbi.nlm.nih.gov/pubmed/35955847
http://dx.doi.org/10.3390/ijms23158714
_version_ 1784766308920852480
author De Plano, Laura M.
Calabrese, Giovanna
Conoci, Sabrina
Guglielmino, Salvatore P. P.
Oddo, Salvatore
Caccamo, Antonella
author_facet De Plano, Laura M.
Calabrese, Giovanna
Conoci, Sabrina
Guglielmino, Salvatore P. P.
Oddo, Salvatore
Caccamo, Antonella
author_sort De Plano, Laura M.
collection PubMed
description Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of these disorders. While the causes of such a lack of therapies can be attributed to various reasons, the disappointing results of recent clinical trials suggest the need for novel and innovative approaches. Since its discovery, there has been a growing excitement around the potential for CRISPR-Cas9 mediated gene editing to identify novel mechanistic insights into disease pathogenesis and to mediate accurate gene therapy. To this end, the literature is rich with experiments aimed at generating novel models of these disorders and offering proof-of-concept studies in preclinical animal models validating the great potential and versatility of this gene-editing system. In this review, we provide an overview of how the CRISPR-Cas9 systems have been used in these neurodegenerative disorders.
format Online
Article
Text
id pubmed-9368966
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93689662022-08-12 Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders De Plano, Laura M. Calabrese, Giovanna Conoci, Sabrina Guglielmino, Salvatore P. P. Oddo, Salvatore Caccamo, Antonella Int J Mol Sci Review Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of these disorders. While the causes of such a lack of therapies can be attributed to various reasons, the disappointing results of recent clinical trials suggest the need for novel and innovative approaches. Since its discovery, there has been a growing excitement around the potential for CRISPR-Cas9 mediated gene editing to identify novel mechanistic insights into disease pathogenesis and to mediate accurate gene therapy. To this end, the literature is rich with experiments aimed at generating novel models of these disorders and offering proof-of-concept studies in preclinical animal models validating the great potential and versatility of this gene-editing system. In this review, we provide an overview of how the CRISPR-Cas9 systems have been used in these neurodegenerative disorders. MDPI 2022-08-05 /pmc/articles/PMC9368966/ /pubmed/35955847 http://dx.doi.org/10.3390/ijms23158714 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Plano, Laura M.
Calabrese, Giovanna
Conoci, Sabrina
Guglielmino, Salvatore P. P.
Oddo, Salvatore
Caccamo, Antonella
Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title_full Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title_fullStr Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title_full_unstemmed Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title_short Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
title_sort applications of crispr-cas9 in alzheimer’s disease and related disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368966/
https://www.ncbi.nlm.nih.gov/pubmed/35955847
http://dx.doi.org/10.3390/ijms23158714
work_keys_str_mv AT deplanolauram applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders
AT calabresegiovanna applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders
AT conocisabrina applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders
AT guglielminosalvatorepp applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders
AT oddosalvatore applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders
AT caccamoantonella applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders